bcl 2 d17c4 rabbit mab (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
97
Structured Review
Cell Signaling Technology Inc
bcl 2 d17c4 rabbit mab
Bcl 2 D17c4 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 2009 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl-2+(d17c4)/Bcl-2+Rabbit+mAb/pm41857115-129-14-55
Average 97 stars, based on 2009 article reviews
Bcl 2 D17c4 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 2009 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/bcl-2+(d17c4)/Bcl-2+Rabbit+mAb/pm41857115-129-14-55
Average 97 stars, based on 2009 article reviews
bcl 2 d17c4 rabbit mab - by Bioz Stars,
2026-09
97/100 stars
Images
Related Articles
Blocking Assay:Article Title: Exploring the therapeutic mechanism of kaempferol in acute lung injury: Network pharmacology and experimental validation. Article Snippet: Acute lung injury (ALI) is a common and life-threatening respiratory disorder characterised by severe inflammation and persistently high mortality rates.. Kaempferol (KAE), a natural flavonoid compound, has diverse biological activities and holds potential for therapeutic applications.. In this study, we employed a network pharmacology approach to predict the mechanism through which KAE mitigates ALI; this mechanism was subsequently validated experimentally in a mouse model of ALI. Membrane:Article Title: Exploring the therapeutic mechanism of kaempferol in acute lung injury: Network pharmacology and experimental validation. Article Snippet: Acute lung injury (ALI) is a common and life-threatening respiratory disorder characterised by severe inflammation and persistently high mortality rates.. Kaempferol (KAE), a natural flavonoid compound, has diverse biological activities and holds potential for therapeutic applications.. In this study, we employed a network pharmacology approach to predict the mechanism through which KAE mitigates ALI; this mechanism was subsequently validated experimentally in a mouse model of ALI. Western Blot:Article Title: Carnosic Acid Activates the STING/IRF3 Pathway to Induce Nitric Oxide-Mediated Apoptosis in Osteosarcoma Cells. Article Snippet: Transient transfections were performed using LipofectamineTM 3000 reagent (Thermo Fisher Scientific, Waltham, MA, USA; Cat# L3000008) according to the manufacturer’s instructions. .. For Western blotting and immunohistochemistry, primary antibodies included antiSTING (CST, Danvers, MA, USA; Cat# 13647), anti-TBK1 (CST, Cat# 3504), anti-p-TBK1 (Ser172, CST, Cat# 5483), anti-IRF-3 (CST, Cat# 11904), anti-p-IRF-3 (Ser396, CST, Cat# 4947), anti-cleaved caspase-3 (CST, Cat# 9664), anti-PARP (CST, Cat# 9542), anti-Bax (CST, Cat# 5023), anti-Bcl-2 (CST, Cat# 3498), Immunohistochemistry:Article Title: Carnosic Acid Activates the STING/IRF3 Pathway to Induce Nitric Oxide-Mediated Apoptosis in Osteosarcoma Cells. Article Snippet: Transient transfections were performed using LipofectamineTM 3000 reagent (Thermo Fisher Scientific, Waltham, MA, USA; Cat# L3000008) according to the manufacturer’s instructions. .. For Western blotting and immunohistochemistry, primary antibodies included antiSTING (CST, Danvers, MA, USA; Cat# 13647), anti-TBK1 (CST, Cat# 3504), anti-p-TBK1 (Ser172, CST, Cat# 5483), anti-IRF-3 (CST, Cat# 11904), anti-p-IRF-3 (Ser396, CST, Cat# 4947), anti-cleaved caspase-3 (CST, Cat# 9664), anti-PARP (CST, Cat# 9542), anti-Bax (CST, Cat# 5023), anti-Bcl-2 (CST, Cat# 3498), Recombinant:Article Title: Capicua mediates interleukin-2 withdrawal–induced death of activated CD8+ T cells Article Snippet: .. Materials and methods 336 4.1 Reagents and antibodies 337 Reagents and antibodies used in this study were obtained from the indicated sources: 338 Recombinant human IL-2 (SL Pharm, S19991010); Annexin V-FITC/PI Apoptosis Kit 339 (Elabscience, E-CK-A211); Actinomycin D (MCE, HY-17559 ); TrueCut Cas9 340 Protein (Invitrogen, A36498); Nuclear and Cytoplasmic Extraction Reagents 341 (Thermo, 78835); Zombie VioletTM Fixable Viability Kit (BioLegend, 423113); 342 Pacific Blue anti-mouse CD3 Antibody (BioLegend, 100214); FITC anti-mouse CD8a 343 Antibody (BioLegend, 100706); APC anti-mouse CD8a Antibody (BD Pharmingen, 344 553035); PE/Cyanine7 anti-mouse CD3 Antibody (BioLegend, 100220); APC anti-345 mouse IFN-γ Antibody (Invivogen, 17-7311-82); PE-Labeled Mouse H-346 2Kb&B2M&OVA (SIINFEKL) Tetramer Protein (Acrobiosystems, H2A-MP2H7); 347 Capicua Antibody (Novusbio, NB110-59906); anti-FLAG Antibody (Sigma-Aldrich, 348 F3165); β-actin (Sigma-Aldrich, A2228); Bim Antibody (Cell Signaling Technology, 349 2933T); Extraction:Article Title: Capicua mediates interleukin-2 withdrawal–induced death of activated CD8+ T cells Article Snippet: .. Materials and methods 336 4.1 Reagents and antibodies 337 Reagents and antibodies used in this study were obtained from the indicated sources: 338 Recombinant human IL-2 (SL Pharm, S19991010); Annexin V-FITC/PI Apoptosis Kit 339 (Elabscience, E-CK-A211); Actinomycin D (MCE, HY-17559 ); TrueCut Cas9 340 Protein (Invitrogen, A36498); Nuclear and Cytoplasmic Extraction Reagents 341 (Thermo, 78835); Zombie VioletTM Fixable Viability Kit (BioLegend, 423113); 342 Pacific Blue anti-mouse CD3 Antibody (BioLegend, 100214); FITC anti-mouse CD8a 343 Antibody (BioLegend, 100706); APC anti-mouse CD8a Antibody (BD Pharmingen, 344 553035); PE/Cyanine7 anti-mouse CD3 Antibody (BioLegend, 100220); APC anti-345 mouse IFN-γ Antibody (Invivogen, 17-7311-82); PE-Labeled Mouse H-346 2Kb&B2M&OVA (SIINFEKL) Tetramer Protein (Acrobiosystems, H2A-MP2H7); 347 Capicua Antibody (Novusbio, NB110-59906); anti-FLAG Antibody (Sigma-Aldrich, 348 F3165); β-actin (Sigma-Aldrich, A2228); Bim Antibody (Cell Signaling Technology, 349 2933T); Incubation:Article Title: Epigenetic activation of PDLIM7 via H3K27 acetylation mitigates neuroinflammation and neurodegeneration in parkinson’s disease models Article Snippet: Parkinson’s disease (PD) is a chronic neurological disorder predominantly affecting middle-aged and older populations, with a prevalence second only to Alzheimer’s disease, impacting about 1% of individuals over the age of 65 worldwide (Tolosa et al. 2021; Lesage and Trinh 2023).. After cardiovascular and cerebrovascular illnesses and tumors, PD is currently the “third killer” of middle-aged and older persons in China.. Based on reliable statistics, it is predicted that there would be up to 4.94 million PD sufferers in China by 2030 (Li et al. 2019). other:Article Title: Biomimetic hybrid nanocarriers hitchhike neutrophils for targeted ginsenoside Rc delivery to BMSCs: ameliorating postmenopausal osteoporosis via iron homeostasis regulation. Article Snippet: Primary antibodies targeting p53(# 2524), Cleaved-Caspase 3(#9661S), Bax(#2772S) and Bcl-2( Control:Article Title: A novel PGK1 activator improves Alzheimer's disease by regulating glycolysis. Article Snippet: .. Primary antibodies used were as follows: PGK1 (1:1000, Abcam, ab199438), GAPDH (1:1000, Zsbio, TA-08), β-Tubulin (1:1000, Zsbio, TA10), Bcl-2 (1:1000, Cell Signaling Technology, 3498), Bax (1:1000, |